Julia Foldi

1.9k total citations
50 papers, 1.3k citations indexed

About

Julia Foldi is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Julia Foldi has authored 50 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 24 papers in Cancer Research and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Julia Foldi's work include Advanced Breast Cancer Therapies (13 papers), Breast Cancer Treatment Studies (13 papers) and Cancer Genomics and Diagnostics (11 papers). Julia Foldi is often cited by papers focused on Advanced Breast Cancer Therapies (13 papers), Breast Cancer Treatment Studies (13 papers) and Cancer Genomics and Diagnostics (11 papers). Julia Foldi collaborates with scholars based in United States, Poland and Hungary. Julia Foldi's co-authors include Lionel B. Ivashkiv, Xiaoyu Hu, Allen Chung, Margit Kulcsár, Jimmy Zhu, Yue‐Ming Li, Jan Kitajewski, Haixia Xu, Baohong Zhao and Gy. Huszenicza and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Julia Foldi

41 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julia Foldi United States	14	520	381	282	281	256	50	1.3k
Kirsty Moore United Kingdom	9	299 0.6×	273 0.7×	61 0.2×	178 0.6×	178 0.7×	25	1.2k
Sam J. P. Gobin Netherlands	18	1.2k 2.3×	300 0.8×	133 0.5×	243 0.9×	88 0.3×	25	1.5k
Marika De Acetis Italy	7	713 1.4×	802 2.1×	47 0.2×	182 0.6×	134 0.5×	7	1.7k
Shinya Sakaguchi Austria	17	1.2k 2.3×	615 1.6×	42 0.1×	428 1.5×	238 0.9×	31	1.8k
Amos Orlofsky United States	24	1.1k 2.0×	842 2.2×	51 0.2×	419 1.5×	179 0.7×	34	2.1k
Joanna S. Morris United Kingdom	23	178 0.3×	613 1.6×	58 0.2×	447 1.6×	229 0.9×	60	1.5k
Hao Ho United States	16	463 0.9×	516 1.4×	227 0.8×	559 2.0×	169 0.7×	25	1.8k
Yu‐Chung Yang United States	22	539 1.0×	702 1.8×	54 0.2×	487 1.7×	144 0.6×	36	1.5k
Luke M. Williams United States	7	2.4k 4.6×	629 1.7×	33 0.1×	409 1.5×	127 0.5×	7	3.1k
Connor J. Dwyer United States	13	536 1.0×	256 0.7×	25 0.1×	463 1.6×	77 0.3×	25	1.0k

Countries citing papers authored by Julia Foldi

Since Specialization

Citations

This map shows the geographic impact of Julia Foldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Foldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Foldi more than expected).

Fields of papers citing papers by Julia Foldi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Foldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Foldi. The network helps show where Julia Foldi may publish in the future.

Co-authorship network of co-authors of Julia Foldi

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Foldi. A scholar is included among the top collaborators of Julia Foldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Foldi. Julia Foldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maynard, Hannah, et al.. (2026). Abstract PD9-03: Comprehensive genomic profiling and clinically targetable mutations of metastatic invasive lobular and no special type breast cancer. Clinical Cancer Research. 32(4_Supplement). PD9–3.

Green, Richard, et al.. (2026). Abstract PD9-01: Comprehensive Genomic Landscape of Invasive Lobular Carcinoma Reveals Distinct Molecular Subtypes. Clinical Cancer Research. 32(4_Supplement). PD9–1.

Tarantino, Paolo, David Lee, Julia Foldi, et al.. (2025). Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer. ESMO Open. 10(7). 105330–105330. 4 indexed citations

Foldi, Julia, Steffi Oesterreich, Antony Tin, et al.. (2025). Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast. JCO Precision Oncology. 9(9). e2400577–e2400577.

Foldi, Julia, Pamela R. Soulos, Cary P. Gross, et al.. (2025). 314P Outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC) according to BRCA and PD-L1 status. ESMO Open. 10. 104886–104886.

Tarantino, Paolo, Julia Foldi, Pamela R. Soulos, et al.. (2025). Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. JNCI Journal of the National Cancer Institute. 117(11). 2327–2335. 4 indexed citations

Gould, Billie, Xiaohong Wang, Giancarlo Bonora, et al.. (2024). Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer. SHILAP Revista de lepidopterología. 6. 100168–100168. 8 indexed citations

Gould, Billie, Kim Blenman, Julia Foldi, et al.. (2024). Abstract PO5-14-05: Circulating tumor DNA fraction correlates with residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer patients. Cancer Research. 84(9_Supplement). PO5–14. 1 indexed citations

Foldi, Julia, Kim Blenman, Michał Marczyk, et al.. (2024). Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer. Breast Cancer Research and Treatment. 208(2). 369–377. 1 indexed citations

10.

Chen, Fangyuan, Sayali Onkar, Jian Zou, et al.. (2024). Immune infiltration correlates with transcriptomic subtypes in primary estrogen receptor positive invasive lobular breast cancer. npj Precision Oncology. 8(1). 257–257. 1 indexed citations

11.

Nasrazadani, Azadeh, Julia Foldi, Jennifer M. Atkinson, et al.. (2024). Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations. Proceedings of the National Academy of Sciences. 121(31). e2322068121–e2322068121. 7 indexed citations

12.

Foldi, Julia, Anastasia Tsagianni, Max Salganik, et al.. (2023). Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer. BMC Cancer. 23(1). 606–606. 4 indexed citations

13.

Foldi, Julia, Andrea Silber, Tao Qing, et al.. (2022). Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research. 28(17). 3720–3728. 13 indexed citations

14.

Qing, Tao, Hussein Mohsen, Vincent L. Cannataro, et al.. (2022). Cancer Relevance of Human Genes. JNCI Journal of the National Cancer Institute. 114(7). 988–995. 1 indexed citations

15.

Qing, Tao, Thomas Karn, Mariya Rozenblit, et al.. (2022). Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. npj Breast Cancer. 8(1). 119–119. 13 indexed citations

16.

Akingbesote, Ngozi D., Aaron D. Norman, Wanling Zhu, et al.. (2022). A precision medicine approach to metabolic therapy for breast cancer in mice. Communications Biology. 5(1). 478–478. 15 indexed citations

17.

Pusztai, Lajos, et al.. (2019). Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. The Lancet Oncology. 20(7). e390–e396. 57 indexed citations

18.

Foldi, Julia, Sarah S. Mougalian, Andrea Silber, et al.. (2018). Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer. Breast Cancer Research and Treatment. 169(2). 333–340. 14 indexed citations

19.

Huang, Yao-Ting, Dionysios Neofytos, Julia Foldi, et al.. (2016). Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 22(8). 1480–1486. 28 indexed citations

20.

Xu, Haixia, Jimmy Zhu, Sinéad M. Smith, et al.. (2012). Notch–RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nature Immunology. 13(7). 642–650. 353 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact